DYADIC INTERNATIONAL INC

Regulatory Filings • Jul 23, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 23, 2025

Field: Rule-Page

Field: /Rule-Page

Dyadic International, Inc.

(Exact name of registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

Delaware	001-32513	45-0486747
(State
or other jurisdiction of
incorporation or organization)	(Commission File
Number)	(I.R.S.
Employer Identification
Number)

1044 North U.S. Highway One , Suite 201

Jupiter , FL 33477

(Address of principal executive offices and zip code)

(561) 743-8333

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.001 per share | DYAI | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 7.01. Regulation FD Disclosure.

On July 23, 2025, Dyadic International, Inc. (“Dyadic” or the “Company”) posted a presentation entitled “Precision engineered recombinant protein production that redefines performance, scalability and economy” on the Company’s website at www.dyadic.com under the “Investors” tab.

The presentation highlights Dyadic’s strategic transition from a research driven organization to a commercially focused enterprise, with an emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms and focus on commercializing high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing sectors.

Representatives of Dyadic will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the presentation is also attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is being furnished herein:

| Exhibit
Number | Description |
| --- | --- |
| 99.1 | Dyadic International Presentation, “Precision engineered recombinant protein production that redefines performance, scalability and economy”, dated July 23 2025 |
| 104 | Cover page Interactive Data File (embedded within
the Inline XBRL document) |

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 23, 2025

| Dyadic
International, Inc. | |
| --- | --- |
| By: | /s/
Ping Rawson |
| Name: | Ping
Rawson |
| Title: | Chief
Financial Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6LW6r+MMuHSrilDGGeFtclOLWjLT+PZJvabchhkBIzvlyhBiJDa11jQynZZFBiU1bK4dQ4AUZzRm9I93uEvCzwKu2jpVx/foDU/IMemY2jpW/986HtlglEM1DKUM5hThKJgvI9yLo9JTMRVdonFY1KFNBztSyRqf4PXwo1YsMNe8+6YhsNZkE4nE0yB+QUSzhQA/1JL5ZyLJUBKO+ArFhurfetXo5NB0JqxobH2cH+t/BF8x2Sl4=